BioSpace News Archive

The reports at TMR Research provide qualitative solutions that break the barriers of doubt or uncertainties when the stakeholders plan to expand their growth reach.

Fact.MR – A Market Research and Competitive Intelligence Provider: Various invasive medical procedures are susceptible to excessive blood loss, especially cesarean deliveries and major organ surgeries.

A market research conducted by Fact.MR reveals key trends and opportunities in the medical device reprocessing market through 2031.

Since Uruguay became the first country to legalize Marijuana in 2013, many others like Canada have followed suit.

Alligator Bioscience announced that the company has entered into a research collaboration and license agreement with Orion Corporation, a global pharmaceutical company based in Finland, to discover and develop together new bispecific antibody cancer therapeutics

Sai Life Sciences, a leading global Contract Research, Development & Manufacturing Organization, announced the opening of a new biology facility at its integrated R&D campus in Hyderabad, India.

Immunitas Therapeutics, a single cell genomics-based therapeutics company, announced the completion of a $58 million Series B financing led by Agent Capital with participation from Medical Excellence Capital, 120 Capital, Solasta Ventures, Mirae Asset, Ono Venture Investment, The Mark Foundation for Cancer Research, NS Investment, BrightEdge, and The Leukemia & Lymphoma Society Therapy Acceleration Program®.

Cabaletta Bio, Inc., a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases, announced 28-day data from the second dose cohort, at the 100 million cell dose level, in the DesCAARTes™ Phase 1 clinical trial of DSG3-CAART for the treatment of patients with mucosal-dominant pemphigus vulgaris.

AzurRx BioPharma, Inc., a company specializing in the development of targeted, non-systemic therapies for gastrointestinal diseases, announced positive topline results from its Phase 2 Combination Trial evaluating MS1819 in combination with the current standard of care, porcine-derived pancreatic enzyme replacement therapy, for the treatment of severe exocrine pancreatic insufficiency in patients with cystic fibrosis.

Centene Corporation announced that its Nevada subsidiary, SilverSummit Healthplan, Inc., has been awarded a contract from the Nevada Department of Health and Human Services - Health Care Financing and Policy to continue providing managed care services for its Medicaid Managed Care program in both Clark and Washoe Counties.